Drug intelligence / Profile preview

CPC202

Development stage: Preclinical
Lead developer: Alephoson
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
Administration: Ophthalmic

Overview

CPC202 is a small molecule therapeutic candidate being developed by Alephoson for the treatment of various retinal conditions, including diabetic macular edema (DME), retinal vein occlusion (RVO), and non-infectious uveitis (NIU). The asset leverages the company's proprietary Cell-Penetrating Complex (CPC) technology, a peptide-based delivery platform designed to transport drugs across biological barriers such as the blood-retinal barrier. This technology aims to enable the administration of treatments via topical eye drops, providing a non-invasive alternative to the standard-of-care intravitreal injections. CPC202 is currently in IND-enabling studies.

Other names: CPC202CPC-202CPC 202

Beyond the preview

Go deeper on CPC202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPC202.

Explore the full profile